Peptide Gene Therapy for Rare Disease

Peptide Gene Therapy & Rare Disease

47 FDA-approved rare disease drugs (2015-2024)

Peptides account for roughly 10% of drugs approved for rare genetic disorders, and peptide-conjugated delivery systems are now central to the next generation of gene therapies.

Subramanian et al., Drug Discovery Today, 2024

Subramanian et al., Drug Discovery Today, 2024

View as image

Of the roughly 7,000 known rare diseases, fewer than 5% have an FDA-approved treatment.^[1] Gene therapy has changed that equation for a handful of conditions, but the core problem persists: getting nucleic acid cargo past cell membranes, into the right tissue, and to the right intracellular compartment. Peptides are increasingly the answer to that delivery problem. Cell-penetrating peptides, peptide-drug conjugates, and engineered peptide vectors are solving bottlenecks that have stalled gene therapies for Duchenne muscular dystrophy, spinal muscular atrophy, Huntington's disease, cystic fibrosis, and dozens of other rare genetic conditions. This article maps the full landscape of peptide-enabled gene therapy for rare disease, from the basic science of delivery to the clinical programs that have reached patients. For how regulatory and trial design challenges shape this field, see The Challenges of Rare Disease Peptide Clinical Trials. For how orphan drug designations accelerate peptide development, see Peptide Orphan Drugs: How Rare Disease Drives Peptide Innovation.

Why Rare Disease Needs Peptide-Enabled Gene Therapy

Traditional gene therapy relies heavily on viral vectors, primarily adeno-associated viruses (AAVs), to deliver corrective genetic material. This approach has produced landmark approvals: Luxturna for inherited retinal dystrophy, Zolgensma for spinal muscular atrophy, and several CAR-T therapies for rare cancers. But viral vectors carry fundamental limitations. They trigger immune responses that can prevent re-dosing, have strict cargo size limits (roughly 4.7 kb for AAV), and manufacturing costs often push treatment prices above $1 million per patient.^[2]

Peptides address several of these constraints simultaneously. Cell-penetrating peptides (CPPs), typically 5 to 30 amino acids in length with a net positive charge, can shuttle nucleic acid cargo across cell membranes without viral packaging.^[3] Peptide-based vectors offer lower immunogenicity than viral capsids, are synthetically tunable, and can be conjugated directly to antisense oligonucleotides, siRNAs, or CRISPR components. The trade-off: peptide delivery systems are still less efficient than viral vectors for some applications, and no peptide-mediated gene therapy has yet reached full FDA approval as a standalone delivery platform.

Cell-Penetrating Peptides: The Delivery Workhorses

Cell-penetrating peptides entered the gene therapy field through a simple observation: the HIV TAT protein's transactivation domain (residues 47-57) could cross cell membranes and carry cargo with it. Since that discovery, researchers have engineered hundreds of CPP variants optimized for different tissues, cargo types, and uptake pathways.^[4]

The mechanisms of CPP uptake remain debated. Dowaidar's 2024 review in Cellular Signalling mapped three primary routes: direct translocation across the lipid bilayer, macropinocytosis (bulk fluid uptake), and clathrin-mediated endocytosis.^[4] The dominant pathway depends on CPP concentration, cargo size, and cell type. For gene therapy applications, endosomal escape remains the critical bottleneck. Cargo that enters via endocytosis must escape the endosome before lysosomal degradation, and CPP design increasingly focuses on engineering sequences that disrupt endosomal membranes at acidic pH.

Urandur and Bhak's 2023 review in the Annual Review of Chemical and Biomolecular Engineering framed peptide vectors as a distinct engineering strategy for gene delivery, separate from both viral vectors and lipid nanoparticles.^[2] They catalogued peptide architectures including linear cationic sequences, amphipathic helices, branched dendrimeric structures, and self-assembling peptide nanoparticles. Each architecture presents different trade-offs between transfection efficiency, toxicity, and tissue specificity.

Duchenne Muscular Dystrophy: The Flagship Application

Duchenne muscular dystrophy (DMD) has become the proving ground for peptide-conjugated gene therapy. DMD is caused by mutations in the dystrophin gene that disrupt the reading frame, preventing production of functional dystrophin protein. Antisense oligonucleotides (ASOs) can force the cellular splicing machinery to skip the mutated exon, restoring the reading frame and producing a shortened but partially functional dystrophin.

Four unconjugated ASOs have FDA approval for DMD exon skipping: eteplirsen, golodirsen, viltolarsen, and casimersen. All are phosphorodiamidate morpholino oligomers (PMOs). Their limitation: naked PMOs distribute poorly to skeletal and cardiac muscle, producing modest dystrophin restoration of 1-2% of normal levels in patients.^[5]

Conjugating a cell-penetrating peptide to the PMO backbone created the peptide-PMO (PPMO) platform. Tsoumpra et al.'s 2019 review in EBioMedicine documented that PPMOs in mouse models produced 10- to 100-fold more dystrophin than equivalent doses of naked PMOs, with improved distribution to cardiac tissue, a critical gap for unconjugated ASOs.^[5] The peptide component, typically an arginine-rich sequence like (RXRRBR)2 or the proprietary R6Gly peptide, drives cellular uptake and endosomal escape.

Sarepta Therapeutics advanced the PPMO concept to clinical trials with SRP-5051 (vesleteplirsen), an R6Gly-conjugated PMO targeting exon 51. Phase 2 MOMENTUM trial data showed mean dystrophin expression of 5.17% and mean exon skipping of 11.11% after 28 weeks at the target dose, substantially exceeding eteplirsen's clinical performance. However, Sarepta discontinued the program after observing prolonged hypomagnesemia in some participants, a class effect related to the arginine-rich peptide's interaction with renal tubular cells.

Other companies continued PPMO development with modified approaches to the toxicity problem. PepGen's PGN-EDO51 uses a proprietary Enhanced Delivery Oligonucleotide technology, a modified PPMO chemistry that showed high exon 51 skipping and a favorable safety profile in Phase 1 healthy volunteer testing. Dyne Therapeutics' DYNE-251 takes a different approach entirely, conjugating the PMO to an antibody fragment targeting the transferrin receptor (TFRC) rather than a cationic CPP, aiming for receptor-mediated muscle uptake with reduced renal toxicity.

On the manufacturing side, Ghosh et al. (2025) in Methods described click chemistry-based conjugation approaches that could simplify the synthesis of peptide-ASO conjugates for DMD.^[6] Their method uses bioorthogonal copper-free click reactions to join peptide and ASO components, producing more homogeneous conjugates than traditional thiol-maleimide chemistry. Manufacturing scalability matters acutely for rare disease, where small patient populations make cost-per-treatment a determining factor in commercial viability.

Spinal Muscular Atrophy: Multiple Peptide Approaches

Spinal muscular atrophy (SMA), the most common genetic cause of infant death, results from mutations in the SMN1 gene. The related SMN2 gene produces mostly truncated protein due to exon 7 skipping, but antisense oligonucleotides can redirect SMN2 splicing to include exon 7, increasing functional SMN protein. Nusinersen (Spinraza), an ASO administered intrathecally, became the first approved treatment for SMA in 2016.

Leckie et al.'s 2024 review in Molecules examined how cell-penetrating peptide conjugation could transform SMA treatment by enabling systemic ASO delivery rather than requiring repeated intrathecal injections.^[7] CPP-conjugated ASOs targeting SMN2 exon 7 inclusion showed improved biodistribution to motor neurons in preclinical models, potentially allowing intravenous administration instead of the invasive lumbar puncture procedure nusinersen requires.

Nakevska et al.'s 2023 review in the European Journal of Cell Biology detailed the remaining challenges: achieving sufficient CNS penetration with systemically administered peptide-ASO conjugates, managing off-target effects in peripheral tissues, and establishing dosing regimens that maintain therapeutic ASO levels without toxicity.^[8]

A different peptide approach to SMA emerged from Boido et al.'s 2023 study in PNAS. Rather than delivering gene-modifying cargo, their team tested MR-409, a synthetic agonist of growth hormone-releasing hormone (GHRH), in SMA mouse models.^[9] The peptide agonist increased circulating IGF-1 levels, which in turn upregulated SMN protein expression through a signaling pathway independent of splicing correction. Treated mice showed improved motor neuron survival, increased muscle fiber size, and extended lifespan. This represents a peptide therapeutic approach that complements gene therapy rather than serving as a delivery vehicle for it.

Chimeric and Engineered CPPs: Designing Better Shuttles

One limitation of early CPPs was their relatively modest delivery efficiency compared to viral vectors. Fadzen et al.'s 2019 study in Biochemistry addressed this by creating chimeric CPPs, fusing sequences from different peptide families to achieve synergistic delivery.^[10] Their chimeras combined elements of penetratin (from the Drosophila Antennapedia homeodomain) with Bac7 (a proline-rich antimicrobial peptide), producing conjugates that delivered PMOs with 5-fold greater exon-skipping activity than either parent sequence alone.

The study demonstrated that CPP delivery is not a simple function of charge or hydrophobicity. Specific sequence combinations create emergent properties, likely through cooperative effects on membrane interaction and endosomal escape. This finding opened a design space for engineering application-specific CPPs rather than relying on a small set of canonical sequences like TAT, penetratin, and polyarginine.

The implications for rare disease are practical. Different genetic disorders affect different tissues, and each tissue presents unique membrane compositions, endocytic machinery, and intracellular trafficking. A CPP optimized for skeletal muscle uptake in DMD may perform poorly in motor neurons for SMA or in hepatocytes for metabolic disorders. Chimeric design provides a systematic framework for tissue-specific optimization rather than the trial-and-error approach that characterized early CPP development.

Myotonic Dystrophy: Defining the Delivery Threshold

Myotonic dystrophy type 1 (DM1) presents a different gene therapy challenge. The disease is caused by expanded CUG repeats in the DMPK mRNA, which sequester the splicing regulator MBNL1 in nuclear foci. ASOs can release MBNL1 by binding to and degrading the toxic RNA.

Van Agtmaal et al.'s 2019 study in FASEB Journal established a critical parameter: the minimum nuclear ASO concentration required for therapeutic effect in DM1 cells.^[11] Their measurements showed that ASOs needed to reach concentrations of approximately 1-5 micromolar in the nucleus to disrupt CUG repeat foci and restore MBNL1 function. This threshold defines the delivery challenge for peptide-conjugated ASOs in DM1: the CPP must not only cross the cell membrane but also achieve sufficient nuclear accumulation.

This quantitative framework is directly applicable to peptide-ASO conjugate design for other repeat expansion disorders, including Huntington's disease and several spinocerebellar ataxias. It also establishes a benchmark for evaluating CPP performance: a successful peptide delivery system for DM1 must achieve micromolar nuclear concentrations, not just demonstrate membrane crossing. Most published CPP studies report total cellular uptake without distinguishing nuclear from cytoplasmic accumulation, making Van Agtmaal et al.'s subcellular quantification approach a model for the field.

Huntington's Disease: Peptides Against Protein Aggregation

Huntington's disease (HD) results from expanded CAG repeats in the huntingtin gene, producing a mutant protein (mHtt) with an elongated polyglutamine tract that drives toxic aggregation. Khan et al.'s 2023 study in ACS Medicinal Chemistry Letters identified three peptide sequences that inhibited mHtt aggregation in vitro.^[12]

The peptides HHGANSLSLVSQD, HGLHSMHNKLTR, and WMFPSLKLLDYH were selected from phage display libraries and tested against mutant huntingtin exon 1 fragments. All three prevented the formation of fibrillar aggregates and reduced cellular toxicity in HD cell models. Northwestern University researchers subsequently developed peptide-brush polymers incorporating these sequences, which rescued neurons in HD mouse models.

The challenge for HD peptide therapeutics is blood-brain barrier penetration. Free peptides are rapidly degraded by serum proteases and have limited CNS access. Approaches under investigation include conjugation to transferrin receptor-binding peptides for receptor-mediated transcytosis, and direct CSF administration analogous to nusinersen's delivery route. For how GHK-Cu modulates thousands of genes through a different mechanism, peptide-gene interactions extend beyond traditional gene therapy.

Cystic Fibrosis: Peptides as Both Treatment and Delivery Tool

Cystic fibrosis (CF), caused by mutations in the CFTR chloride channel gene, illustrates how peptides contribute to rare disease treatment through multiple mechanisms simultaneously.

Bellet et al.'s 2021 study in the European Journal of Medicinal Chemistry demonstrated that thymosin alpha-1, a 28-amino acid immunomodulatory peptide, produced extrapulmonary benefits in CF beyond its known immune effects.^[13] The peptide reduced gut inflammation, improved intestinal barrier function, and partially restored CFTR-dependent chloride transport in CF cell models. This suggests thymosin alpha-1 acts as a proteostasis regulator, potentially aiding the folding and trafficking of mutant CFTR protein.

On the delivery side, CPPs are being investigated as vehicles for mRNA and ASO therapies targeting CFTR. The lung's epithelial barrier presents unique delivery challenges: inhaled therapeutics must penetrate the mucus layer (which is abnormally thick and viscous in CF), cross the airway epithelium, and avoid immune clearance by the dense populations of macrophages and neutrophils in CF airways. The antimicrobial peptide environment in CF lungs is itself altered. Chen et al. (2004) measured beta-defensin and LL-37 levels in bronchoalveolar lavage fluid from CF patients, finding disrupted antimicrobial peptide profiles that contribute to the chronic infection cycle. Peptide-nucleic acid conjugates designed for pulmonary delivery must contend with this hostile biochemical environment in addition to the physical barriers. No CF-specific peptide delivery system has reached clinical trials, but the combination of CFTR modulator therapy (ivacaftor, lumacaftor) with peptide-delivered gene correction represents one of the most promising avenues for the approximately 10% of CF patients whose mutations are not addressed by current modulators.

CRISPR Delivery: Peptides as Gene Editing Couriers

The most recent frontier for peptide-enabled gene therapy is CRISPR-Cas9 delivery. Viral vectors remain the dominant delivery method for in vivo gene editing, but their cargo limits, immunogenicity, and risk of insertional mutagenesis have driven interest in non-viral alternatives.

Oktem et al.'s 2023 study in Pharmaceutics demonstrated that amphipathic cell-penetrating peptides could deliver preformed Cas9 ribonucleoprotein (RNP) complexes into human cells, achieving gene editing and correction at efficiencies relevant to therapeutic applications.^[14] The RNP approach is particularly attractive for rare disease because the Cas9 protein is active transiently, reducing off-target editing risk compared to DNA-based delivery that produces sustained Cas9 expression.

For rare diseases caused by single-gene mutations, peptide-delivered CRISPR offers a path toward one-time curative treatments without the immunological complications of viral vectors. The Cure Rare Disease initiative has demonstrated the feasibility of personalized (N-of-1) gene editing approaches for individual patients with unique DMD mutations. Peptide delivery systems could make these patient-specific therapies more accessible by simplifying manufacturing: synthesizing a custom CPP-RNP conjugate requires days to weeks, compared to months for producing a custom AAV vector. The speed advantage matters most in pediatric rare diseases where disease progression creates urgency for early intervention.

Exosome-Peptide Hybrids: Biomimetic Delivery

Xu et al.'s 2021 study in ACS Applied Materials & Interfaces described an engineered exosome platform decorated with targeting peptides for ASO delivery.^[15] Exosomes, naturally occurring extracellular vesicles, combine low immunogenicity with inherent ability to cross biological barriers including the blood-brain barrier.

By engineering targeting peptides onto the exosome surface, the researchers achieved cell-type-specific delivery of therapeutic ASOs. This hybrid approach merges the biocompatibility of natural vesicles with the targeting specificity of engineered peptides, and is being explored for CNS-targeting rare disease applications including SMA, HD, and lysosomal storage disorders.

Stapled Peptides: Stabilizing Therapeutic Structures

Beyond delivery, peptides themselves serve as therapeutic agents in rare disease. Hydrocarbon-stapled peptides, first demonstrated by Walensky et al. in a landmark 2004 Science paper, use a chemical crosslink to lock peptides into their bioactive alpha-helical conformation.^[16] The staple simultaneously increases protease resistance, cell permeability, and target binding affinity.

Stapled peptides have entered clinical development for several rare diseases, including cancers driven by protein-protein interactions that are difficult to target with small molecules. The technology represents a convergence of peptide engineering and gene-level intervention: by disrupting specific protein interactions that drive disease phenotypes, stapled peptides achieve gene-pathway-level effects without modifying the genome itself. For how liposomal delivery systems address similar stability challenges, the field is converging on multiple delivery solutions.

The Broader Peptide Toolkit for Genetic Disease

Subramanian et al.'s 2024 review in Drug Discovery Today provided the most comprehensive mapping of the peptide-genetic disease landscape to date.^[1] They documented three distinct roles peptides play:

As delivery vehicles: CPPs, peptide-drug conjugates, and peptide-decorated nanoparticles shuttle nucleic acid therapies into target cells. This is the most active area of development, with multiple candidates in clinical trials for DMD, SMA, and other neuromuscular diseases.

As direct therapeutics: Peptides that modulate gene expression pathways, inhibit toxic protein aggregation, or restore protein function (as with thymosin alpha-1 in CF) treat genetic disease without directly modifying genes.

As diagnostic biomarkers: Peptide-based assays detect specific mutations, protein misfolding states, or disease-associated peptide fragments, enabling earlier diagnosis of rare genetic conditions.

The review noted that between 2015 and 2024, the FDA approved 47 drugs for rare genetic disorders, with peptides comprising approximately 10% of approvals. Several additional peptide-based therapies are in late-stage clinical development.

What Remains Unsolved

Peptide-enabled gene therapy for rare disease faces concrete technical barriers. Tissue specificity remains limited: most CPPs distribute broadly rather than targeting specific organs. Endosomal escape efficiency, typically estimated at 1-2% for standard CPPs, means the vast majority of internalized cargo is degraded before reaching its target. Manufacturing scale-up for peptide-nucleic acid conjugates lacks the standardization that viral vector production has achieved over two decades. And clinical toxicity signals, as seen with the hypomagnesemia that halted SRP-5051, demonstrate that peptide delivery components carry their own safety profiles that require careful characterization.

The regulatory framework for peptide-conjugated gene therapies also lacks clear precedent. These products combine elements of biologics (the peptide), nucleic acid therapeutics (the ASO or CRISPR component), and potentially gene therapy (if the payload modifies genomic DNA), creating classification questions that affect development timelines and approval pathways. The FDA's 2025 trio of draft guidances on cell and gene therapy for rare diseases signaled increasing flexibility in trial design, including acceptance of smaller sample sizes and innovative endpoints, but did not specifically address the peptide-conjugate category.

Patient access is another unsolved dimension. Rare disease populations are small by definition, and the intersection of a specific rare disease with a specific mutation amenable to peptide-conjugated therapy can produce target populations of hundreds or even dozens of patients worldwide. Manufacturing, distributing, and pricing treatments for these micro-populations requires business models that the pharmaceutical industry is still developing. The orphan drug pathway provides market exclusivity incentives, but the gap between approval and patient access remains wide for many rare disease therapies. For how this regulatory landscape shapes peptide drug development specifically, see Peptide Orphan Drugs: How Rare Disease Drives Peptide Innovation. For a deeper analysis of trial design challenges, see The Challenges of Rare Disease Peptide Clinical Trials.

The Bottom Line

Peptides have become central to the next generation of gene therapies for rare disease, functioning as delivery vehicles for antisense oligonucleotides, CRISPR components, and mRNA, and as direct therapeutics targeting disease-driving protein interactions. The strongest clinical evidence exists for peptide-conjugated PMOs in Duchenne muscular dystrophy, where PPMOs have demonstrated 10-100x improvements in dystrophin production over naked ASOs in preclinical models. Active programs span SMA, Huntington's disease, cystic fibrosis, myotonic dystrophy, and CRISPR-based approaches to single-gene disorders. The field remains constrained by tissue specificity, endosomal escape efficiency, and regulatory uncertainty, but the pace of preclinical and clinical development has accelerated substantially since 2020.

Frequently Asked Questions

What is peptide gene therapy for rare disease?

Peptide gene therapy uses short amino acid sequences to deliver gene-modifying cargo (antisense oligonucleotides, siRNA, or CRISPR components) into cells affected by rare genetic disorders. Cell-penetrating peptides, typically 5-30 amino acids long, cross cell membranes and carry therapeutic nucleic acids to their intracellular targets. Between 2015 and 2024, peptide-based approaches accounted for roughly 10% of FDA-approved drugs for rare genetic disorders (Subramanian et al., 2024).

How do cell-penetrating peptides deliver gene therapies?

Cell-penetrating peptides (CPPs) enter cells through three main pathways: direct translocation across the lipid bilayer, macropinocytosis, and clathrin-mediated endocytosis (Dowaidar et al., 2024). The dominant pathway depends on CPP concentration, cargo size, and cell type. For gene therapy, the critical challenge is endosomal escape, where cargo that enters via endocytosis must exit the endosome before lysosomal degradation destroys it.

What rare diseases are being treated with peptide-conjugated antisense therapy?

The most advanced programs target Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). In DMD, peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) produced 10-100x more dystrophin than unconjugated PMOs in mouse models (Tsoumpra et al., 2019). For SMA, CPP-conjugated antisense oligonucleotides may enable systemic delivery, avoiding the repeated intrathecal injections required by nusinersen. Additional targets include myotonic dystrophy type 1 and Huntington's disease.

Can peptides deliver CRISPR gene editing for genetic disorders?

Amphipathic cell-penetrating peptides have delivered CRISPR-Cas9 ribonucleoprotein (RNP) complexes into human cells at therapeutically relevant editing efficiencies (Oktem et al., 2023). The RNP delivery approach is transient, meaning Cas9 is active briefly then degraded, which reduces off-target editing risk compared to viral vector delivery that produces sustained Cas9 expression. This technology is in preclinical development for rare single-gene disorders.

What are the limitations of peptide gene therapy?

Current limitations include low tissue specificity (most CPPs distribute broadly rather than targeting specific organs), poor endosomal escape efficiency (typically 1-2% of internalized cargo reaches its target), manufacturing challenges for peptide-nucleic acid conjugates, and incomplete safety profiles. The SRP-5051 program for DMD was discontinued after peptide-related hypomagnesemia in clinical trials. No peptide-mediated gene therapy has received full FDA approval as a standalone delivery platform.

How do peptide gene therapies compare to viral vector gene therapies?

Viral vectors (primarily AAV) achieve higher transfection efficiency and have produced approved gene therapies like Zolgensma and Luxturna. Peptide delivery systems offer lower immunogenicity, no cargo size restrictions, the ability to re-dose without immune neutralization, and lower manufacturing costs. Peptide-conjugated ASOs for DMD have reached Phase 2 clinical trials, while peptide-mediated CRISPR delivery remains in preclinical stages. The two approaches are complementary rather than competing.